XOMA Royalty Corp.
XOMA Royalty Corp. (XOMA) Stock Competitors & Peer Comparison
See (XOMA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XOMA | $41.79 | +0.60% | 526.5M | 26.74 | $1.57 | N/A |
| NVO | $44.00 | -0.64% | 200.3B | 10.53 | $4.28 | +3.99% |
| VRTX | $429.87 | -1.02% | 109.3B | 25.55 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $644.82 | +2.30% | 66.9B | 15.86 | $40.97 | +0.56% |
| ARGX | $809.63 | +1.49% | 49.8B | 35.73 | $22.52 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $295.81 | +0.51% | 39.8B | 74.80 | $3.99 | N/A |
| RVMD | $151.82 | +3.07% | 31.9B | -21.12 | -$7.11 | N/A |
| UTHR | $561.88 | -0.87% | 23.9B | 20.85 | $27.05 | N/A |
Stock Comparison
XOMA vs NVO Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, NVO has a market cap of 200.3B. Regarding current trading prices, XOMA is priced at $41.79, while NVO trades at $44.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas NVO's P/E ratio is 10.53. In terms of profitability, XOMA's ROE is +0.30%, compared to NVO's ROE of +0.66%. Regarding short-term risk, XOMA is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check NVO's competition here
XOMA vs VRTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, VRTX has a market cap of 109.3B. Regarding current trading prices, XOMA is priced at $41.79, while VRTX trades at $429.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas VRTX's P/E ratio is 25.55. In terms of profitability, XOMA's ROE is +0.30%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, XOMA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check VRTX's competition here
XOMA vs VRNA Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, XOMA is priced at $41.79, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas VRNA's P/E ratio is -102.80. In terms of profitability, XOMA's ROE is +0.30%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, XOMA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check VRNA's competition here
XOMA vs REGN Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, REGN has a market cap of 66.9B. Regarding current trading prices, XOMA is priced at $41.79, while REGN trades at $644.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas REGN's P/E ratio is 15.86. In terms of profitability, XOMA's ROE is +0.30%, compared to REGN's ROE of +0.14%. Regarding short-term risk, XOMA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check REGN's competition here
XOMA vs ARGX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ARGX has a market cap of 49.8B. Regarding current trading prices, XOMA is priced at $41.79, while ARGX trades at $809.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ARGX's P/E ratio is 35.73. In terms of profitability, XOMA's ROE is +0.30%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, XOMA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ARGX's competition here
XOMA vs SGEN Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, XOMA is priced at $41.79, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas SGEN's P/E ratio is -57.19. In terms of profitability, XOMA's ROE is +0.30%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, XOMA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check SGEN's competition here
XOMA vs ALNY Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ALNY has a market cap of 39.8B. Regarding current trading prices, XOMA is priced at $41.79, while ALNY trades at $295.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ALNY's P/E ratio is 74.80. In terms of profitability, XOMA's ROE is +0.30%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, XOMA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ALNY's competition here
XOMA vs RVMD Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, RVMD has a market cap of 31.9B. Regarding current trading prices, XOMA is priced at $41.79, while RVMD trades at $151.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas RVMD's P/E ratio is -21.12. In terms of profitability, XOMA's ROE is +0.30%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, XOMA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check RVMD's competition here
XOMA vs UTHR Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, UTHR has a market cap of 23.9B. Regarding current trading prices, XOMA is priced at $41.79, while UTHR trades at $561.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas UTHR's P/E ratio is 20.85. In terms of profitability, XOMA's ROE is +0.30%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, XOMA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check UTHR's competition here
XOMA vs INSM Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, INSM has a market cap of 23.4B. Regarding current trading prices, XOMA is priced at $41.79, while INSM trades at $107.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas INSM's P/E ratio is -18.73. In terms of profitability, XOMA's ROE is +0.30%, compared to INSM's ROE of -1.30%. Regarding short-term risk, XOMA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check INSM's competition here
XOMA vs ROIV Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ROIV has a market cap of 23.2B. Regarding current trading prices, XOMA is priced at $41.79, while ROIV trades at $31.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ROIV's P/E ratio is -27.70. In terms of profitability, XOMA's ROE is +0.30%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, XOMA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ROIV's competition here
XOMA vs BNTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, XOMA is priced at $41.79, while BNTX trades at $90.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas BNTX's P/E ratio is -15.34. In terms of profitability, XOMA's ROE is +0.30%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, XOMA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check BNTX's competition here
XOMA vs RPRX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, RPRX has a market cap of 22.8B. Regarding current trading prices, XOMA is priced at $41.79, while RPRX trades at $52.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas RPRX's P/E ratio is 27.93. In terms of profitability, XOMA's ROE is +0.30%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, XOMA is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check RPRX's competition here
XOMA vs BGNE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, XOMA is priced at $41.79, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas BGNE's P/E ratio is -22.55. In terms of profitability, XOMA's ROE is +0.30%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, XOMA is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check BGNE's competition here
XOMA vs INCY Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, INCY has a market cap of 19.4B. Regarding current trading prices, XOMA is priced at $41.79, while INCY trades at $96.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas INCY's P/E ratio is 13.71. In terms of profitability, XOMA's ROE is +0.30%, compared to INCY's ROE of +0.29%. Regarding short-term risk, XOMA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check INCY's competition here
XOMA vs MRNA Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, MRNA has a market cap of 19.1B. Regarding current trading prices, XOMA is priced at $41.79, while MRNA trades at $47.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas MRNA's P/E ratio is -5.91. In terms of profitability, XOMA's ROE is +0.30%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, XOMA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check MRNA's competition here
XOMA vs DNA-WT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, XOMA is priced at $41.79, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, XOMA's ROE is +0.30%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, XOMA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check DNA-WT's competition here
XOMA vs GMAB Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, GMAB has a market cap of 16.7B. Regarding current trading prices, XOMA is priced at $41.79, while GMAB trades at $26.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas GMAB's P/E ratio is 20.61. In terms of profitability, XOMA's ROE is +0.30%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, XOMA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check GMAB's competition here
XOMA vs NBIX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, XOMA is priced at $41.79, while NBIX trades at $153.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas NBIX's P/E ratio is 23.83. In terms of profitability, XOMA's ROE is +0.30%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, XOMA is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check NBIX's competition here
XOMA vs JAZZ Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, XOMA is priced at $41.79, while JAZZ trades at $238.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas JAZZ's P/E ratio is 2172.82. In terms of profitability, XOMA's ROE is +0.30%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, XOMA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check JAZZ's competition here
XOMA vs ASND Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ASND has a market cap of 14.9B. Regarding current trading prices, XOMA is priced at $41.79, while ASND trades at $241.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ASND's P/E ratio is 27.49. In terms of profitability, XOMA's ROE is +0.30%, compared to ASND's ROE of -56.42%. Regarding short-term risk, XOMA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ASND's competition here
XOMA vs SMMT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, SMMT has a market cap of 13.9B. Regarding current trading prices, XOMA is priced at $41.79, while SMMT trades at $17.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas SMMT's P/E ratio is -11.25. In terms of profitability, XOMA's ROE is +0.30%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, XOMA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check SMMT's competition here
XOMA vs BBIO Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, XOMA is priced at $41.79, while BBIO trades at $67.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas BBIO's P/E ratio is -18.24. In terms of profitability, XOMA's ROE is +0.30%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, XOMA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check BBIO's competition here
XOMA vs KRTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, XOMA is priced at $41.79, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas KRTX's P/E ratio is -28.09. In terms of profitability, XOMA's ROE is +0.30%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, XOMA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check KRTX's competition here
XOMA vs EXEL Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, EXEL has a market cap of 12.5B. Regarding current trading prices, XOMA is priced at $41.79, while EXEL trades at $49.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas EXEL's P/E ratio is 16.52. In terms of profitability, XOMA's ROE is +0.30%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, XOMA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check EXEL's competition here
XOMA vs IONS Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, XOMA is priced at $41.79, while IONS trades at $74.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas IONS's P/E ratio is -37.34. In terms of profitability, XOMA's ROE is +0.30%, compared to IONS's ROE of -0.59%. Regarding short-term risk, XOMA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check IONS's competition here
XOMA vs AXSM Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, AXSM has a market cap of 11.9B. Regarding current trading prices, XOMA is priced at $41.79, while AXSM trades at $230.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas AXSM's P/E ratio is -62.16. In terms of profitability, XOMA's ROE is +0.30%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, XOMA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check AXSM's competition here
XOMA vs MDGL Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, XOMA is priced at $41.79, while MDGL trades at $504.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas MDGL's P/E ratio is -38.12. In terms of profitability, XOMA's ROE is +0.30%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, XOMA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check MDGL's competition here
XOMA vs RNAM Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, XOMA is priced at $41.79, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas RNAM's P/E ratio is -17.39. In terms of profitability, XOMA's ROE is +0.30%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, XOMA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check RNAM's competition here
XOMA vs ARWR Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ARWR has a market cap of 10.9B. Regarding current trading prices, XOMA is priced at $41.79, while ARWR trades at $74.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ARWR's P/E ratio is -33.95. In terms of profitability, XOMA's ROE is +0.30%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, XOMA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ARWR's competition here
XOMA vs CYTK Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, XOMA is priced at $41.79, while CYTK trades at $78.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CYTK's P/E ratio is -11.50. In terms of profitability, XOMA's ROE is +0.30%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, XOMA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check CYTK's competition here
XOMA vs BMRN Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, BMRN has a market cap of 9.7B. Regarding current trading prices, XOMA is priced at $41.79, while BMRN trades at $52.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas BMRN's P/E ratio is 37.74. In terms of profitability, XOMA's ROE is +0.30%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, XOMA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check BMRN's competition here
XOMA vs RXDX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, XOMA is priced at $41.79, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas RXDX's P/E ratio is -56.47. In terms of profitability, XOMA's ROE is +0.30%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, XOMA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check RXDX's competition here
XOMA vs KRYS Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, XOMA is priced at $41.79, while KRYS trades at $300.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas KRYS's P/E ratio is 40.44. In terms of profitability, XOMA's ROE is +0.30%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, XOMA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check KRYS's competition here
XOMA vs IMGN Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, XOMA is priced at $41.79, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas IMGN's P/E ratio is -111.55. In terms of profitability, XOMA's ROE is +0.30%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, XOMA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check IMGN's competition here
XOMA vs IBRX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, IBRX has a market cap of 8.4B. Regarding current trading prices, XOMA is priced at $41.79, while IBRX trades at $7.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas IBRX's P/E ratio is -9.47. In terms of profitability, XOMA's ROE is +0.30%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, XOMA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check IBRX's competition here
XOMA vs BPMC Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, XOMA is priced at $41.79, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas BPMC's P/E ratio is -51.58. In terms of profitability, XOMA's ROE is +0.30%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, XOMA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check BPMC's competition here
XOMA vs CERE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, XOMA is priced at $41.79, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CERE's P/E ratio is -16.47. In terms of profitability, XOMA's ROE is +0.30%, compared to CERE's ROE of -0.72%. Regarding short-term risk, XOMA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check CERE's competition here
XOMA vs HALO Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, XOMA is priced at $41.79, while HALO trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas HALO's P/E ratio is 24.20. In terms of profitability, XOMA's ROE is +0.30%, compared to HALO's ROE of +1.26%. Regarding short-term risk, XOMA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check HALO's competition here
XOMA vs ABVX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ABVX has a market cap of 7.9B. Regarding current trading prices, XOMA is priced at $41.79, while ABVX trades at $120.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ABVX's P/E ratio is -21.36. In terms of profitability, XOMA's ROE is +0.30%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, XOMA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ABVX's competition here
XOMA vs NUVL Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, XOMA is priced at $41.79, while NUVL trades at $100.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas NUVL's P/E ratio is -16.88. In terms of profitability, XOMA's ROE is +0.30%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, XOMA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check NUVL's competition here
XOMA vs MTSR Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, XOMA is priced at $41.79, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas MTSR's P/E ratio is -23.58. In terms of profitability, XOMA's ROE is +0.30%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, XOMA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check MTSR's competition here
XOMA vs TECH Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, TECH has a market cap of 7.3B. Regarding current trading prices, XOMA is priced at $41.79, while TECH trades at $46.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas TECH's P/E ratio is 66.71. In terms of profitability, XOMA's ROE is +0.30%, compared to TECH's ROE of +0.05%. Regarding short-term risk, XOMA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check TECH's competition here
XOMA vs IMVT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, IMVT has a market cap of 7.2B. Regarding current trading prices, XOMA is priced at $41.79, while IMVT trades at $34.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas IMVT's P/E ratio is -13.29. In terms of profitability, XOMA's ROE is +0.30%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, XOMA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check IMVT's competition here
XOMA vs PRAX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, XOMA is priced at $41.79, while PRAX trades at $335.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas PRAX's P/E ratio is -25.05. In terms of profitability, XOMA's ROE is +0.30%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, XOMA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check PRAX's competition here
XOMA vs CELC Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CELC has a market cap of 6.8B. Regarding current trading prices, XOMA is priced at $41.79, while CELC trades at $137.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CELC's P/E ratio is -35.98. In terms of profitability, XOMA's ROE is +0.30%, compared to CELC's ROE of -2.45%. Regarding short-term risk, XOMA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check CELC's competition here
XOMA vs MRUS Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, XOMA is priced at $41.79, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas MRUS's P/E ratio is -17.05. In terms of profitability, XOMA's ROE is +0.30%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, XOMA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check MRUS's competition here
XOMA vs PCVX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, PCVX has a market cap of 6.8B. Regarding current trading prices, XOMA is priced at $41.79, while PCVX trades at $46.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas PCVX's P/E ratio is -6.85. In terms of profitability, XOMA's ROE is +0.30%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, XOMA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check PCVX's competition here
XOMA vs ACLX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, XOMA is priced at $41.79, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ACLX's P/E ratio is -28.27. In terms of profitability, XOMA's ROE is +0.30%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, XOMA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check ACLX's competition here
XOMA vs KYMR Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, KYMR has a market cap of 6.6B. Regarding current trading prices, XOMA is priced at $41.79, while KYMR trades at $78.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas KYMR's P/E ratio is -22.53. In terms of profitability, XOMA's ROE is +0.30%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, XOMA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check KYMR's competition here
XOMA vs RETA Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, XOMA is priced at $41.79, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas RETA's P/E ratio is -66.29. In terms of profitability, XOMA's ROE is +0.30%, compared to RETA's ROE of +0.47%. Regarding short-term risk, XOMA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check RETA's competition here
XOMA vs PTGX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, PTGX has a market cap of 6.5B. Regarding current trading prices, XOMA is priced at $41.79, while PTGX trades at $100.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas PTGX's P/E ratio is -55.73. In terms of profitability, XOMA's ROE is +0.30%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, XOMA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check PTGX's competition here
XOMA vs CORT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CORT has a market cap of 6.3B. Regarding current trading prices, XOMA is priced at $41.79, while CORT trades at $59.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CORT's P/E ratio is 173.71. In terms of profitability, XOMA's ROE is +0.30%, compared to CORT's ROE of +0.08%. Regarding short-term risk, XOMA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check CORT's competition here
XOMA vs RYTM Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, XOMA is priced at $41.79, while RYTM trades at $90.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas RYTM's P/E ratio is -28.96. In terms of profitability, XOMA's ROE is +0.30%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, XOMA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check RYTM's competition here
XOMA vs ALKS Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ALKS has a market cap of 6.2B. Regarding current trading prices, XOMA is priced at $41.79, while ALKS trades at $36.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ALKS's P/E ratio is 41.08. In terms of profitability, XOMA's ROE is +0.30%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, XOMA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ALKS's competition here
XOMA vs CNTA Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, XOMA is priced at $41.79, while CNTA trades at $39.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CNTA's P/E ratio is -22.33. In terms of profitability, XOMA's ROE is +0.30%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, XOMA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check CNTA's competition here
XOMA vs TGTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, TGTX has a market cap of 6.1B. Regarding current trading prices, XOMA is priced at $41.79, while TGTX trades at $39.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas TGTX's P/E ratio is 13.90. In terms of profitability, XOMA's ROE is +0.30%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, XOMA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check TGTX's competition here
XOMA vs PTCT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, XOMA is priced at $41.79, while PTCT trades at $69.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas PTCT's P/E ratio is -27.96. In terms of profitability, XOMA's ROE is +0.30%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, XOMA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check PTCT's competition here
XOMA vs SRRK Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, XOMA is priced at $41.79, while SRRK trades at $47.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas SRRK's P/E ratio is -14.02. In terms of profitability, XOMA's ROE is +0.30%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, XOMA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check SRRK's competition here
XOMA vs BLTE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, XOMA is priced at $41.79, while BLTE trades at $144.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas BLTE's P/E ratio is -62.33. In terms of profitability, XOMA's ROE is +0.30%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, XOMA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check BLTE's competition here
XOMA vs CGON Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, XOMA is priced at $41.79, while CGON trades at $64.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CGON's P/E ratio is -27.68. In terms of profitability, XOMA's ROE is +0.30%, compared to CGON's ROE of -0.23%. Regarding short-term risk, XOMA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check CGON's competition here
XOMA vs COGT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, XOMA is priced at $41.79, while COGT trades at $32.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas COGT's P/E ratio is -15.17. In terms of profitability, XOMA's ROE is +0.30%, compared to COGT's ROE of -0.83%. Regarding short-term risk, XOMA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check COGT's competition here
XOMA vs CDTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, XOMA is priced at $41.79, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CDTX's P/E ratio is -19.77. In terms of profitability, XOMA's ROE is +0.30%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, XOMA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check CDTX's competition here
XOMA vs ABCM Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, XOMA is priced at $41.79, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, XOMA's ROE is +0.30%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, XOMA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check ABCM's competition here
XOMA vs ISEE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, XOMA is priced at $41.79, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ISEE's P/E ratio is -22.44. In terms of profitability, XOMA's ROE is +0.30%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, XOMA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check ISEE's competition here
XOMA vs LQDA Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, LQDA has a market cap of 5.5B. Regarding current trading prices, XOMA is priced at $41.79, while LQDA trades at $60.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas LQDA's P/E ratio is 363.35. In terms of profitability, XOMA's ROE is +0.30%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, XOMA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check LQDA's competition here
XOMA vs APLS Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, XOMA is priced at $41.79, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas APLS's P/E ratio is 38.35. In terms of profitability, XOMA's ROE is +0.30%, compared to APLS's ROE of +0.40%. Regarding short-term risk, XOMA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check APLS's competition here
XOMA vs LEGN Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, XOMA is priced at $41.79, while LEGN trades at $28.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas LEGN's P/E ratio is -20.38. In terms of profitability, XOMA's ROE is +0.30%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, XOMA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check LEGN's competition here
XOMA vs FBIOX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, XOMA is priced at $41.79, while FBIOX trades at $24.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas FBIOX's P/E ratio is N/A. In terms of profitability, XOMA's ROE is +0.30%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, XOMA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check FBIOX's competition here
XOMA vs APGE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, APGE has a market cap of 5B. Regarding current trading prices, XOMA is priced at $41.79, while APGE trades at $81.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas APGE's P/E ratio is -18.78. In terms of profitability, XOMA's ROE is +0.30%, compared to APGE's ROE of -0.33%. Regarding short-term risk, XOMA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check APGE's competition here
XOMA vs MIRM Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, MIRM has a market cap of 4.9B. Regarding current trading prices, XOMA is priced at $41.79, while MIRM trades at $97.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas MIRM's P/E ratio is -7.13. In terms of profitability, XOMA's ROE is +0.30%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, XOMA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check MIRM's competition here
XOMA vs TERN Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, XOMA is priced at $41.79, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas TERN's P/E ratio is -51.41. In terms of profitability, XOMA's ROE is +0.30%, compared to TERN's ROE of -0.20%. Regarding short-term risk, XOMA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check TERN's competition here
XOMA vs CRSP Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, XOMA is priced at $41.79, while CRSP trades at $48.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CRSP's P/E ratio is -7.87. In terms of profitability, XOMA's ROE is +0.30%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, XOMA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check CRSP's competition here
XOMA vs FOLD Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, XOMA is priced at $41.79, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas FOLD's P/E ratio is -161.00. In terms of profitability, XOMA's ROE is +0.30%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, XOMA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check FOLD's competition here
XOMA vs AKRO Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, XOMA is priced at $41.79, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas AKRO's P/E ratio is -14.57. In terms of profitability, XOMA's ROE is +0.30%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, XOMA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check AKRO's competition here
XOMA vs ALPN Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, XOMA is priced at $41.79, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ALPN's P/E ratio is -101.52. In terms of profitability, XOMA's ROE is +0.30%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, XOMA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check ALPN's competition here
XOMA vs CAI Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, XOMA is priced at $41.79, while CAI trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CAI's P/E ratio is -5.69. In terms of profitability, XOMA's ROE is +0.30%, compared to CAI's ROE of +0.06%. Regarding short-term risk, XOMA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check CAI's competition here
XOMA vs MANE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, XOMA is priced at $41.79, while MANE trades at $104.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas MANE's P/E ratio is -39.69. In terms of profitability, XOMA's ROE is +0.30%, compared to MANE's ROE of -0.95%. Regarding short-term risk, XOMA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check MANE's competition here
XOMA vs LGND Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, XOMA is priced at $41.79, while LGND trades at $218.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas LGND's P/E ratio is 28.39. In terms of profitability, XOMA's ROE is +0.30%, compared to LGND's ROE of +0.16%. Regarding short-term risk, XOMA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check LGND's competition here
XOMA vs SYRE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, XOMA is priced at $41.79, while SYRE trades at $72.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas SYRE's P/E ratio is -33.89. In terms of profitability, XOMA's ROE is +0.30%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, XOMA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check SYRE's competition here
XOMA vs XENE Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, XOMA is priced at $41.79, while XENE trades at $54.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas XENE's P/E ratio is -11.63. In terms of profitability, XOMA's ROE is +0.30%, compared to XENE's ROE of -0.49%. Regarding short-term risk, XOMA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check XENE's competition here
XOMA vs OPT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, XOMA is priced at $41.79, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas OPT's P/E ratio is -1.52. In terms of profitability, XOMA's ROE is +0.30%, compared to OPT's ROE of +0.88%. Regarding short-term risk, XOMA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check OPT's competition here
XOMA vs NAMS Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, NAMS has a market cap of 4.2B. Regarding current trading prices, XOMA is priced at $41.79, while NAMS trades at $36.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas NAMS's P/E ratio is -20.08. In terms of profitability, XOMA's ROE is +0.30%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, XOMA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check NAMS's competition here
XOMA vs MRTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, XOMA is priced at $41.79, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas MRTX's P/E ratio is -4.82. In terms of profitability, XOMA's ROE is +0.30%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, XOMA is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check MRTX's competition here
XOMA vs KNSA Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, KNSA has a market cap of 4.1B. Regarding current trading prices, XOMA is priced at $41.79, while KNSA trades at $55.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas KNSA's P/E ratio is 59.65. In terms of profitability, XOMA's ROE is +0.30%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, XOMA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check KNSA's competition here
XOMA vs TVTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, XOMA is priced at $41.79, while TVTX trades at $43.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas TVTX's P/E ratio is -86.98. In terms of profitability, XOMA's ROE is +0.30%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, XOMA is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check TVTX's competition here
XOMA vs CPRX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, XOMA is priced at $41.79, while CPRX trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CPRX's P/E ratio is 18.06. In terms of profitability, XOMA's ROE is +0.30%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, XOMA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check CPRX's competition here
XOMA vs CRNX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, XOMA is priced at $41.79, while CRNX trades at $36.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CRNX's P/E ratio is -7.06. In terms of profitability, XOMA's ROE is +0.30%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, XOMA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check CRNX's competition here
XOMA vs RYZB Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, XOMA is priced at $41.79, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas RYZB's P/E ratio is -57.86. In terms of profitability, XOMA's ROE is +0.30%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, XOMA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check RYZB's competition here
XOMA vs CBAY Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, XOMA is priced at $41.79, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas CBAY's P/E ratio is -32.81. In terms of profitability, XOMA's ROE is +0.30%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, XOMA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check CBAY's competition here
XOMA vs DNTH Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, XOMA is priced at $41.79, while DNTH trades at $88.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas DNTH's P/E ratio is -20.97. In terms of profitability, XOMA's ROE is +0.30%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, XOMA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check DNTH's competition here
XOMA vs VCYT Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, XOMA is priced at $41.79, while VCYT trades at $44.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas VCYT's P/E ratio is 41.84. In terms of profitability, XOMA's ROE is +0.30%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, XOMA is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check VCYT's competition here
XOMA vs ACAD Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, XOMA is priced at $41.79, while ACAD trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ACAD's P/E ratio is 9.48. In terms of profitability, XOMA's ROE is +0.30%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, XOMA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ACAD's competition here
XOMA vs SWTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, XOMA is priced at $41.79, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas SWTX's P/E ratio is -13.78. In terms of profitability, XOMA's ROE is +0.30%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, XOMA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMA.Check SWTX's competition here
XOMA vs EWTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, XOMA is priced at $41.79, while EWTX trades at $32.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas EWTX's P/E ratio is -19.77. In terms of profitability, XOMA's ROE is +0.30%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, XOMA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check EWTX's competition here
XOMA vs TLX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, XOMA is priced at $41.79, while TLX trades at $10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas TLX's P/E ratio is -514.00. In terms of profitability, XOMA's ROE is +0.30%, compared to TLX's ROE of -0.02%. Regarding short-term risk, XOMA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check TLX's competition here
XOMA vs ERAS Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, ERAS has a market cap of 3.5B. Regarding current trading prices, XOMA is priced at $41.79, while ERAS trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas ERAS's P/E ratio is -11.96. In terms of profitability, XOMA's ROE is +0.30%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, XOMA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check ERAS's competition here
XOMA vs VKTX Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, XOMA is priced at $41.79, while VKTX trades at $29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas VKTX's P/E ratio is -7.09. In terms of profitability, XOMA's ROE is +0.30%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, XOMA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check VKTX's competition here
XOMA vs DNLI Comparison May 2026
XOMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMA stands at 526.5M. In comparison, DNLI has a market cap of 3B. Regarding current trading prices, XOMA is priced at $41.79, while DNLI trades at $18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMA currently has a P/E ratio of 26.74, whereas DNLI's P/E ratio is -6.54. In terms of profitability, XOMA's ROE is +0.30%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, XOMA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for XOMA.Check DNLI's competition here